CO6761320A2 - Derivados de piperidina puenteada - Google Patents
Derivados de piperidina puenteadaInfo
- Publication number
- CO6761320A2 CO6761320A2 CO13176486A CO13176486A CO6761320A2 CO 6761320 A2 CO6761320 A2 CO 6761320A2 CO 13176486 A CO13176486 A CO 13176486A CO 13176486 A CO13176486 A CO 13176486A CO 6761320 A2 CO6761320 A2 CO 6761320A2
- Authority
- CO
- Colombia
- Prior art keywords
- lower alkyl
- halogen
- ring
- substituted
- amyloid
- Prior art date
Links
- 150000003053 piperidines Chemical class 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 9
- 229910052736 halogen Inorganic materials 0.000 abstract 7
- 125000005843 halogen group Chemical group 0.000 abstract 5
- 125000001072 heteroaryl group Chemical group 0.000 abstract 4
- 102000013455 Amyloid beta-Peptides Human genes 0.000 abstract 3
- 108010090849 Amyloid beta-Peptides Proteins 0.000 abstract 3
- 125000003545 alkoxy group Chemical group 0.000 abstract 3
- 125000004432 carbon atom Chemical group C* 0.000 abstract 3
- 125000005842 heteroatom Chemical group 0.000 abstract 3
- 229910052757 nitrogen Inorganic materials 0.000 abstract 3
- 229910052717 sulfur Inorganic materials 0.000 abstract 3
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 150000002367 halogens Chemical group 0.000 abstract 2
- 208000018282 ACys amyloidosis Diseases 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 201000010374 Down Syndrome Diseases 0.000 abstract 1
- 208000007487 Familial Cerebral Amyloid Angiopathy Diseases 0.000 abstract 1
- 208000032849 Hereditary cerebral hemorrhage with amyloidosis Diseases 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 208000005314 Multi-Infarct Dementia Diseases 0.000 abstract 1
- 201000004810 Vascular dementia Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 208000017004 dementia pugilistica Diseases 0.000 abstract 1
- 230000008021 deposition Effects 0.000 abstract 1
- 125000002541 furyl group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La presente invención se refiere a compuestos de la fórmula:en la que:hetarilo I es un grupo heteroarilo de cinco o seis eslabones, que contiene de 1 a 3 heteroátomos elegidos entre S y N;hetarilo II es un grupo heteroarilo de seis eslabones, que contiene de 1 a 3 heteroátomos elegidos entre S y N, o es un sistema cíclico de dos miembros que contiene de 1 a 4 heteroátomos elegidos entre S y N, de los que por lo menos un anillo es de naturaleza aromática;Res alquilo inferior, alcoxi inferior, alquilo inferior sustituido por halógeno o halógeno;Res alquilo inferior, alquilo inferior sustituido por halógeno, halógeno, alcoxi inferior, cicloalquilo sustituido por alquilo inferior o alquilo inferior sustituido por halógeno,o es alquilo inferior sustituido por hidroxi, o es furilo, o es O-bencilo,(CH)-fenilo, opcionalmente sustituido por halógeno, alcoxi inferior, alquilo inferior sustituido por halógeno, alquilo inferior o por ciano;Res hidrógeno o alquilo inferior;Y es (CH)-, -CHOCH-, -CHO-, CHS-, -CHSCH- y está unido a dos de los átomos de carbono del anillo, la unión se realiza con los átomos de carbono a y b del anillo o con los átomos de carbono c y d del anillo;p es el número 0 ó 1;m es el número 0, 1 ó 2; si m es 2, entonces Rpuede ser igual o diferente;n es el número 2 ó 3;o es el número 0, 1 ó 2, si o es 2, entonces Rpuede ser igual o diferente; o a sus sales de adición de ácido farmacéuticamente activas.Los compuestos presentes de la fórmula I son moduladores de betaamiloide y por ello pueden ser útiles para el tratamiento o prevención de una enfermedad asociada con la deposición de ß-amiloide en el cerebro, en particular la enfermedad de Alzheimer y otras enfermedades, como son la angiopatía cerebral amiloide, la hemorragia cerebral hereditaria con amiloidosis de tipo Dutch (HCHWA-D), la demencia multiinfarto, la demencia pugilística y el síndrome de Down.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11156587 | 2011-03-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6761320A2 true CO6761320A2 (es) | 2013-09-30 |
Family
ID=45757448
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO13176486A CO6761320A2 (es) | 2011-03-02 | 2013-07-25 | Derivados de piperidina puenteada |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US8703763B2 (es) |
| EP (1) | EP2681214B1 (es) |
| JP (1) | JP5753591B2 (es) |
| KR (1) | KR101550122B1 (es) |
| CN (1) | CN103403003B (es) |
| BR (1) | BR112013021924A2 (es) |
| CA (1) | CA2824239A1 (es) |
| CL (1) | CL2013002474A1 (es) |
| CO (1) | CO6761320A2 (es) |
| CR (1) | CR20130358A (es) |
| EA (1) | EA025035B1 (es) |
| EC (1) | ECSP13012858A (es) |
| IL (1) | IL227251A (es) |
| MA (1) | MA34964B1 (es) |
| MX (1) | MX2013009031A (es) |
| MY (1) | MY167264A (es) |
| PE (1) | PE20140250A1 (es) |
| PH (1) | PH12013501658A1 (es) |
| SG (1) | SG193239A1 (es) |
| UA (1) | UA110368C2 (es) |
| WO (1) | WO2012116965A1 (es) |
| ZA (1) | ZA201305322B (es) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101496701B1 (ko) * | 2007-04-25 | 2015-03-12 | 닛산 가가쿠 고교 가부시키 가이샤 | 폴리이미드 전구체, 폴리이미드, 및 화상 형성 하층막 도포액 |
| US11090297B2 (en) | 2013-06-21 | 2021-08-17 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating huntington's disease |
| CN107922437B (zh) * | 2015-09-09 | 2021-12-10 | 豪夫迈·罗氏有限公司 | 桥连哌啶衍生物 |
| BR112018009281B1 (pt) | 2015-11-12 | 2023-10-31 | F. Hoffmann-La Roche Ag | Composições para tratar atrofia muscular espinhal e seu uso |
| MX382671B (es) | 2015-12-10 | 2025-03-13 | Ptc Therapeutics Inc | Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington |
| JP6872550B2 (ja) * | 2015-12-10 | 2021-05-19 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 架橋されたピペリジン誘導体 |
| WO2018001918A1 (en) | 2016-06-27 | 2018-01-04 | F. Hoffmann-La Roche Ag | Triazolopyridines as gamma-secretase modulators |
| JP6980751B2 (ja) | 2016-07-14 | 2021-12-15 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 縮合ピリミジン誘導体 |
| FI3504187T3 (fi) | 2016-08-24 | 2025-04-05 | Prilenia Neurotherapeutics Ltd | Pridopidiinin käyttö toiminnallisen heikkenemisen hoitoa varten |
| AR109829A1 (es) * | 2016-09-29 | 2019-01-30 | Hoffmann La Roche | Derivados de piperidina puenteados |
| JP6956175B2 (ja) * | 2016-10-04 | 2021-11-02 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 二環式ヘテロアリール誘導体 |
| CN109641912B (zh) * | 2016-11-01 | 2021-10-29 | 豪夫迈·罗氏有限公司 | 二环杂芳基衍生物 |
| AR110122A1 (es) * | 2016-11-08 | 2019-02-27 | Hoffmann La Roche | Fenoxitriazoles |
| CA3047096A1 (en) | 2016-12-16 | 2018-06-21 | Pipeline Therapeutics, Inc. | Methods of treating cochlear synaptopathy |
| JP7376471B2 (ja) | 2017-06-05 | 2023-11-08 | ピーティーシー セラピューティクス， インコーポレイテッド | ハンチントン病を処置するための化合物 |
| MX2019015580A (es) | 2017-06-28 | 2020-07-28 | Ptc Therapeutics Inc | Metodos para tratar la enfermedad de huntington. |
| MX2019015578A (es) | 2017-06-28 | 2020-07-28 | Ptc Therapeutics Inc | Metodos para tratar la enfermedad de huntington. |
| JP6903825B2 (ja) * | 2017-12-19 | 2021-07-14 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | γ−セクレターゼのモジュレーターとしてのトリアゾロピリジン |
| US11370802B2 (en) | 2018-01-22 | 2022-06-28 | Hoffmann-La Roche, Inc. | Triazolo-azepine derivatives |
| JP7399870B2 (ja) | 2018-03-27 | 2023-12-18 | ピーティーシー セラピューティクス， インコーポレイテッド | ハンチントン病を処置するための化合物 |
| LT3814357T (lt) | 2018-06-27 | 2024-06-25 | Ptc Therapeutics, Inc. | Heterocikliniai ir heteroarilų junginiai, skirti hantingtono ligos gydymui |
| EA202092899A1 (ru) | 2018-06-27 | 2021-05-14 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | Гетероарильные соединения для лечения болезни гентингтона |
| US11685746B2 (en) | 2018-06-27 | 2023-06-27 | Ptc Therapeutics, Inc. | Heteroaryl compounds for treating Huntington's disease |
| PT3846903T (pt) | 2018-09-03 | 2023-12-14 | Hoffmann La Roche | Derivados heteroarílicos bicíclicos |
| EP3894411B1 (en) * | 2018-12-13 | 2024-06-19 | F. Hoffmann-La Roche AG | 7-phenoxy-n-(3-azabicyclo[3.2.1]octan-8-yl)-6,7-dihydro-5h-pyrrolo[1,2-b][1,2,4]triazol-2-amine derivatives and related compounds as gamma-secretase modulators for the treatment of alzheimer's disease |
| PL3902779T3 (pl) * | 2018-12-27 | 2023-05-15 | F. Hoffmann-La Roche Ag | Sposób wytwarzania egzo-n-(3-azabicyklo[3.2.1]oktan- 8-ylo)-karbaminianu tert-butylu |
| CN113372364B (zh) * | 2020-03-10 | 2024-05-31 | 明慧医药（上海）有限公司 | 一类jak激酶抑制剂及其制备和应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6432985B2 (en) | 2000-04-25 | 2002-08-13 | Hoffmann-La Roche Inc. | Neuroprotective substituted piperidine compounds with activity as NMDA NR2B subtype selective antagonists |
| US7037902B2 (en) | 2002-07-03 | 2006-05-02 | Receptron, Inc. | Affinity small molecules for the EPO receptor |
| HU227684B1 (en) | 2003-08-29 | 2011-11-28 | Sanofi Aventis | Adamantane and azabicyclo-octane and nonane derivatives and their use as dpp-iv inhibitors |
| JP4871290B2 (ja) * | 2005-10-06 | 2012-02-08 | 日本曹達株式会社 | 架橋環状アミン化合物および有害生物防除剤 |
| EP2257541B1 (en) | 2008-02-22 | 2013-08-14 | F. Hoffmann-La Roche AG | Modulators for amyloid beta |
| US20110190269A1 (en) | 2010-02-01 | 2011-08-04 | Karlheinz Baumann | Gamma secretase modulators |
| US8486967B2 (en) | 2010-02-17 | 2013-07-16 | Hoffmann-La Roche Inc. | Heteroaryl substituted piperidines |
-
2012
- 2012-02-27 US US13/405,404 patent/US8703763B2/en not_active Expired - Fee Related
- 2012-02-28 JP JP2013555846A patent/JP5753591B2/ja not_active Expired - Fee Related
- 2012-02-28 SG SG2013065107A patent/SG193239A1/en unknown
- 2012-02-28 MY MYPI2013003198A patent/MY167264A/en unknown
- 2012-02-28 WO PCT/EP2012/053301 patent/WO2012116965A1/en not_active Ceased
- 2012-02-28 MA MA36238A patent/MA34964B1/fr unknown
- 2012-02-28 KR KR1020137025946A patent/KR101550122B1/ko not_active Expired - Fee Related
- 2012-02-28 UA UAA201311595A patent/UA110368C2/uk unknown
- 2012-02-28 CA CA2824239A patent/CA2824239A1/en not_active Abandoned
- 2012-02-28 PE PE2013002000A patent/PE20140250A1/es not_active Application Discontinuation
- 2012-02-28 EP EP12705884.0A patent/EP2681214B1/en not_active Not-in-force
- 2012-02-28 EA EA201391209A patent/EA025035B1/ru not_active IP Right Cessation
- 2012-02-28 CN CN201280011284.3A patent/CN103403003B/zh not_active Expired - Fee Related
- 2012-02-28 BR BR112013021924-6A patent/BR112013021924A2/pt not_active IP Right Cessation
- 2012-02-28 MX MX2013009031A patent/MX2013009031A/es active IP Right Grant
- 2012-02-28 PH PH1/2013/501658A patent/PH12013501658A1/en unknown
-
2013
- 2013-06-27 IL IL227251A patent/IL227251A/en active IP Right Grant
- 2013-07-15 ZA ZA2013/05322A patent/ZA201305322B/en unknown
- 2013-07-23 CR CR20130358A patent/CR20130358A/es unknown
- 2013-07-25 CO CO13176486A patent/CO6761320A2/es unknown
- 2013-08-28 CL CL2013002474A patent/CL2013002474A1/es unknown
- 2013-08-30 EC ECSP13012858 patent/ECSP13012858A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2681214B1 (en) | 2017-03-22 |
| CA2824239A1 (en) | 2012-09-07 |
| MY167264A (en) | 2018-08-14 |
| NZ612525A (en) | 2015-08-28 |
| EA201391209A1 (ru) | 2013-12-30 |
| EP2681214A1 (en) | 2014-01-08 |
| WO2012116965A1 (en) | 2012-09-07 |
| CN103403003A (zh) | 2013-11-20 |
| JP5753591B2 (ja) | 2015-07-22 |
| EA025035B1 (ru) | 2016-11-30 |
| US8703763B2 (en) | 2014-04-22 |
| ZA201305322B (en) | 2014-04-30 |
| PH12013501658A1 (en) | 2013-10-07 |
| AU2012222426A1 (en) | 2013-07-11 |
| PE20140250A1 (es) | 2014-03-12 |
| IL227251A (en) | 2016-09-29 |
| IL227251A0 (en) | 2013-09-30 |
| ECSP13012858A (es) | 2013-10-31 |
| MA34964B1 (fr) | 2014-03-01 |
| CL2013002474A1 (es) | 2014-05-30 |
| CR20130358A (es) | 2013-10-03 |
| KR101550122B1 (ko) | 2015-09-03 |
| US20120225884A1 (en) | 2012-09-06 |
| SG193239A1 (en) | 2013-10-30 |
| CN103403003B (zh) | 2016-09-14 |
| MX2013009031A (es) | 2013-09-02 |
| BR112013021924A2 (pt) | 2020-10-20 |
| UA110368C2 (xx) | 2015-12-25 |
| KR20130140142A (ko) | 2013-12-23 |
| JP2014506903A (ja) | 2014-03-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6761320A2 (es) | Derivados de piperidina puenteada | |
| AR080177A1 (es) | Derivados de piperidina, un procedimiento para su preparacion, y su uso en medicamentos para el tratamiento de enfermedades mentales asociadas a la deposicion del beta-amiloide en el cerebro. | |
| AR121661A2 (es) | Esteroides neuroactivos, composiciones y usos de los mismos | |
| AR074304A1 (es) | Moduladores heterociclicos de gamma- secretasa | |
| AR070130A1 (es) | Compuestos moduladores de beta-amiloide, un proceso para su obtencion, el uso del compuesto para la fabricacion de un medicamento y dicho medicamento | |
| PE20200008A1 (es) | Isoquinolinas como inhibidores de hpk1 | |
| MX2018000592A (es) | Derivados de etinilo como moduladores del receptor de glutamato metabotropico. | |
| AR096371A1 (es) | 2-fenilimidazo[1,2-a]pirimidinas | |
| AR107010A1 (es) | Derivados de piperidina puenteados | |
| AR092628A1 (es) | Piridinonas biciclicas | |
| AR066509A1 (es) | Derivados de tiazol, medicamentos que los contienen, proceso de preparacion y usos como moduladores de beta amiloide. | |
| AR081426A1 (es) | Derivados de pirazol inhibidores del receptor sigma | |
| AR085615A1 (es) | Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen | |
| AR080083A1 (es) | Moduladores de gamma-secretasa | |
| AR084553A1 (es) | DERIVADOS IMIDAZOLICOS HETEROCICLICOS INHIBIDORES DE b-SECRETASA, COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN Y USO DE LOS MISMOS PARA TRATAR ENFERMEDADES NEURODEGENERATIVAS, EN PARTICULAR ALZHEIMER | |
| AR105965A1 (es) | Derivados de piperidina puenteados | |
| AR076008A1 (es) | Derivados de hidroximetil-isoxazol moduladores de receptores gaba a, composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos para el tratamiento del alzheimer y otros trastornos cognitivos. | |
| AR087628A1 (es) | Inhibidores de pde10 de pirimidina | |
| AR087915A1 (es) | N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1 | |
| AR091781A1 (es) | Antagonistas del receptor de 5-ht3 | |
| AR083872A1 (es) | Derivados de acido carbamoil-cicloalquil-acetico sustituidos como inhibidores de nep | |
| EA201590438A1 (ru) | 2-оксо-2,3-дигидроиндолы для лечения расстройств центральной нервной системы | |
| NI201300072A (es) | Derivados de heteroarilo como moduladores nachr alfa 7 | |
| AR110001A1 (es) | Derivados heteroarilo bicíclicos | |
| AR082111A1 (es) | Furopiridinas o tienopiridinas condensadas, composiciones farmaceuticas que las contienen utiles para tratar trastornos psicoticos y del sistema nervioso central, y metodo de preparacion de las mismas |